Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (4)
  • Open Access

    ARTICLE

    Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation

    ZHILI ZHUO#, DONGNI ZHANG#, WENPING LU*, XIAOQING WU, YONGJIA CUI, WEIXUAN ZHANG, MENGFAN ZHANG

    Oncology Research, Vol.32, No.6, pp. 1093-1107, 2024, DOI:10.32604/or.2024.047257 - 23 May 2024

    Abstract Breast cancer is the leading cause of cancer-related deaths in women worldwide, with Hormone Receptor (HR)+ being the predominant subtype. Tamoxifen (TAM) serves as the primary treatment for HR+ breast cancer. However, drug resistance often leads to recurrence, underscoring the need to develop new therapies to enhance patient quality of life and reduce recurrence rates. Artemisinin (ART) has demonstrated efficacy in inhibiting the growth of drug-resistant cells, positioning art as a viable option for counteracting endocrine resistance. This study explored the interaction between artemisinin and tamoxifen through a combined approach of bioinformatics analysis and experimental… More > Graphic Abstract

    Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation

  • Open Access

    ARTICLE

    The effect of natural products combination on MCF-7 cells exceeds tamoxifen therapeutic dose effects in vitro

    ZEINAB KLAAB1, AZIZA HASSAN2, JAWAHER ALBAQAMI1, FAIZAH A. ALMALKI1,*

    BIOCELL, Vol.47, No.4, pp. 891-904, 2023, DOI:10.32604/biocell.2023.026556 - 08 March 2023

    Abstract Cancer remains to be one of the most severe sicknesses globally. Cases have kept rising over the years. Breast cancer (BC), which is among the leading types of cancers and predominantly affects women, is the second leading cause of cancer mortality. Researchers have developed interventions over the years; however, the BC survival rate has not improved since the 1980s. This has created the need for novel drug interventions that would manage and treat BC more effectively. This study focused on using a combination of natural product extracts such as phytoestrogen (Ziziphus jujube) and Tannin nanoparticles (NP99)… More >

  • Open Access

    ARTICLE

    Tannin Nanoparticles (NP99) Enhances the Anticancer Effect of Tamoxifen on ER+ Breast Cancer Cells

    Faizah A. AlMalki1, Aziza M. Hassan2,*, Zeinab M. Klaab1, Soliman Abdulla3, Antonio Pizzi4

    Journal of Renewable Materials, Vol.9, No.12, pp. 2077-2092, 2021, DOI:10.32604/jrm.2021.016173 - 22 June 2021

    Abstract Recently, natural substances in the form of nanoparticles are increasingly being used in different field, particularly in medicines to enhance their beneficial effects in treatment and prevention. Cancer cells of the breast (MCF-7) have been chosen to be examined and treated in vitro with conventional drug Tamoxifen (Tam) and tannin nanoparticles extract (NP99) individually or in combination. MTT reagent has been applied to assess the cell viability and propagation percentage, DNA fragmentation and mRNA relative expression of apoptotic genes to study the cell death pathway. The results showed that Tam and tannin NP99 triggered cytotoxic activity More >

  • Open Access

    ARTICLE

    Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer

    Annemarie E. M. Post*†, Johan Bussink*, Fred C. G. J. Sweep, Paul N. Span*

    Oncology Research, Vol.28, No.1, pp. 33-40, 2020, DOI:10.3727/096504019X15555794826018

    Abstract Tamoxifen-induced radioresistance, reported in vitro, might pose a problem for patients who receive neoadjuvant tamoxifen treatment and subsequently receive radiotherapy after surgery. Previous studies suggested that DNA damage repair or cell cycle genes are involved, and could therefore be targeted to preclude the occurrence of cross-resistance. We aimed to characterize the observed cross-resistance by investigating gene expression of DNA damage repair genes and cell cycle genes in estrogen receptor-positive MCF-7 breast cancer cells that were cultured to tamoxifen resistance. RNA sequencing was performed, and expression of genes characteristic for several DNA damage repair pathways was… More >

Displaying 1-10 on page 1 of 4. Per Page